Last updated on

Journal of Clinical Oncology
Research Hotspot & Journal Scope - advanced


Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.15_SUPPL.4079
Pembrolizumab (pembro) for advanced biliary adenocarcinoma: Results from the KEYNOTE-028 (KN028) and KEYNOTE-158 (KN158) basket studies.

Yung-Jue Bang · Makoto Ueno · David Malka · Hyun Cheol Chung · Adnan Nagrial · Robin Kate Kelley · Sarina Anne Piha-Paul · Willeke Ros · Antoine Italiano · Kazuhiko Nakagawa · Hope S. Rugo · Filippo de Braud · Andrea Varga · Aaron Richard Hansen · Chao Gao · Suba Krishnan · Kevin Norwood · Toshihiko Doi ·

Medicine
PDF
Journal of Clinical Oncology - DOI: 10.1200/JCO.18.02309
Neoadjuvant Modified FOLFOX6 With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Final Results of the Chinese FOWARC Trial

Yanhong Deng · Pan Chi · Ping Lan · Lei Wang · Weiqing Chen · Long Cui · Daoda Chen · Jie Cao · Hongbo Wei · Xiang Peng · Zonghai Huang · Guanfu Cai · Ren Zhao · Zhongcheng Huang · Lin Xu · Hongfeng Zhou · Yisheng Wei · Hao Zhang · Jian Zheng · Yan Huang · Zhiyang Zhou · Yue Cai · Liang Kang · Meijin Huang · Xiaojian Wu · Junsheng Peng · Donglin Ren · Jianping Wang ·

Medicine
PDF
Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.15_SUPPL.6018
Activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients with advanced RET-altered thyroid cancers.

Matthew H. Taylor · Justin F. Gainor · Mimi I-Nan Hu · Viola W. Zhu · Gilberto Lopes · Sophie Leboulleux · Marcia S. Brose · Martin Schuler · Daniel W. Bowles · Dong-Wan Kim · Christina S. Baik · Elena Garralda · Chia-Chi Lin · Douglas Adkins · Debashis Sarker · Giuseppe Curigliano · Hui Zhang · Corinne Clifford · Christopher D. Turner · Vivek Subbiah ·

Medicine
PDF
Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.4_SUPPL.129
Phase I/II study of ramucirumab plus nivolumab in patients in second-line treatment for advanced gastric adenocarcinoma (NivoRam study).

Hiroki Hara · Hirokazu Shoji · Daisuke Takahari · Taito Esaki · Nozomu Machida · Kengo Nagashima · Kazunori Aoki · Kazufumi Honda · Takahiro Miyamoto · Narikazu Boku · Ken Kato ·

Medicine
PDF
Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.15_SUPPL.2514
A phase I study of ALX148, a CD47 blocker, in combination with established anticancer antibodies in patients with advanced malignancy.

Laura Quan Man Chow · Justin F. Gainor · Nehal J. Lakhani · Hyun Cheol Chung · Keun-Wook Lee · Jeeyun Lee · Patricia LoRusso · Yung-Jue Bang · F. Stephen Hodi · Philip Fanning · Yonggang Zhao · Feng Jin · Hong Wan · Jaume Pons · Sophia Randolph · Wells A. Messersmith ·

Medicine
PDF

Objective To investigate the clinical effects of Kangai-Guben-Xiaozheng decoction based on pathogenesis theory of cancerous toxin combined with TP scheme in the treatment of advanced ovarian carcinoma in elderly patients.

The effects of Kangai-Guben-Xiaozheng decoction combined with TP scheme in the treatment of advanced ovarian carcinoma in elderly patients [10.3760/CMA.J.ISSN.1673-4246.2019.10.002]


For this reason PD-L1 testing is mandatory for patients with advanced NSCLC for whom an immune checkpoint inhibitor treatment is appropriate.

What impacts the cost-effectiveness of PD-L1 testing in non-small cell lung cancer? [10.1016/j.lungcan.2019.03.011]


BackgroundAdvanced esophageal squamous cell cancer (ESCC) is frequently diagnosed in elderly patients.

A multicenter open-label phase II trial to evaluate nivolumab and ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer (RAMONA) [10.1186/s12885-019-5446-2]


This review discusses recent studies that have used plasma NGS in advanced colorectal cancer and summarizes the clinical applications, as well as the technical challenges involved in adopting this technique in a clinically beneficial oncological practice.

Clinical Application of Next-Generation Sequencing as A Liquid Biopsy Technique in Advanced Colorectal Cancer: A Trick or A Treat? [10.3390/cancers11101573]


Agents such as abiraterone acetate, which provides additional androgen suppression by inhibiting cytochrome P450 17A (CYP17A), have improved survival outcomes of patients with advanced prostate cancer.

Abiraterone acetate to treat metastatic castration-resistant prostate cancer in combination with prednisone. [10.1358/dot.2019.55.1.2914339]


Highly Related Keywords from advanced

Research Hotspot

Journal of Clinical Oncology

Research Hotspot
Journal of Clinical Oncology Related Journals

Popular Journals